Psoriasis: Severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity

European Journal of Dermatology

Volumn 16, Issue 2, 2006, Pages 167-171

  Van De Kerkhof, P C M ^a   Kragballe, K ^a  

^a NONE

Author keywords

Biological agents; PASI; Percent BSA; Psoriasis; Systemic treatment; Topical treatment

Indexed keywords

ARTICLE; BODY SURFACE; CLINICAL PRACTICE; CONSENSUS; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHOTOTHERAPY; PROSPECTIVE STUDY; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; SELF EVALUATION; SYSTEMIC THERAPY; TOPICAL TREATMENT; VISUAL ANALOG SCALE; WORKSHOP;

HUMANS; PROSPECTIVE STUDIES; PSORIASIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 33645566578     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003; 14: 158-65.
2. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-91.
3. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-41.
4. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15: 27-9.
5. Finzi AF, Mantovani LG, Belisari A, Italian Association for Studies on Psoriasis. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereal 2001; 15: 320-4.
6. Feldman SR, Fleischer Jr. AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-9.
7. Dubin DB, Tanner W, Ellis R. Biologics for psoriasis. Nature Rev 2003; 2: 855-6.
8. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124: 565-70.
9. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.
10. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality or life. Results from a 1998 National Psoriasis Foundation Patient-Membership survey. Arch Dermatol 2001; 137: 280-4.
11. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
12. Finlay AY. Quality of life measures in dermatology: a practical guide. Br J Dermatol 1997; 136: 305-14.
13. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23: 391-8.
14. Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? Br Med J 1998; 316: 542-5.
15. Kirkby B, Richards H, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72-6.
16. Gottlieb AB, Chaudhari U, Baker DG, et al. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003; 2: 260-6.